LawrenceGLumMD

Oncology • Detroit, MI

Hematologic Oncology

professor of oncoloy, medicine, and immunology and microbiology

Join to view full profile

Dr. Lum is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lum's full profile

Already have an account?

Office
4100 John R
Karmanos Cancer Center
Detroit, MI 48201
Phone+1 800-527-6266

Fax+1 313-576-8767

Education & Training

University of ColoradoResidency, Pediatrics, 1975 - 1976
University of California (San Francisco)Residency, Pediatrics, 1973 - 1975
University of California San Francisco School of MedicineClass of 1973

Certifications & Licensure

VA State Medical License 2016 - 2024
MI State Medical License 1989 - 2017
CA State Medical License 1974 - 2015
WA State Medical License Active through 2013
American Board of Pediatrics Pediatrics

Clinical Trials

Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer Start of enrollment: 2007 Aug 01
Terminated
Phase 2
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer Start of enrollment: 2000 Jan 01
Withdrawn
Phase 1, Phase 2
Biological Therapy in Treating Women With Stage IV Breast Cancer Start of enrollment: 2001 Oct 01
Completed
Phase 1
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 2004 Mar 01
Completed
Phase 1
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2007 Oct 01
Withdrawn
Phase 1
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer Start of enrollment: 2010 Mar 08
Terminated
Phase 2
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery Start of enrollment: 2010 Jul 01
Terminated
Phase 2
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) Start of enrollment: 2011 Aug 17
Completed
Phase 1
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Start of enrollment: 2015 Feb 12
Terminated
Phase 1
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Start of enrollment: 2012 May 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T.
Michael C Brown, Vincent M D'Anniballe, David Boczkowski, Harini Kandadi, Nadeem Sheikh
Cancer Research Communications. 2024-10-01
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies.
Daniel R Reed, Lawrence G Lum
Expert Opinion on Biological Therapy. 2024-08-01
1 citations
Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer.
Elisabeth I Heath, Archana Thakur, Wei Chen, Clara Hwang, Channing J Paller
Cancer Research Communications. 2024-07-01

Lectures

Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) for HER2-negative (0-2+) metastatic breast cancer.
2019 ASCO Annual Meeting - 6/1/2019
Clinical and immune responses using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) for locally advanced or metastatic pancreatic cancer.
2019 ASCO Annual Meeting - 6/1/2019
Targeting advanced pancreatic cancer with activated t cells armed with anti-CD3 x anti-EGFR bispecific antibody.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Pax6 Organizes the Anterior Eye Segment by Guiding Two Distinct Neural Crest WavesJune 17th, 2020
Q&A: Cancer Death Rates Are Falling Nationally. Here’s What’s Happening at UVAJanuary 10th, 2020
Cancer Drug Could Promote Regeneration of Heart TissueFebruary 6th, 2017
Join now to see all

Grant Support

Enhancing Neoadjuvant Chemotherpay Responses With Targeted T CellsNational Cancer Institute2010–2012
Breast Cancer Treatment With Antibody Targeted T CellsNational Cancer Institute2006–2011
Chemical Disruption Of The HH And WNT Pathways In Vertebrate DevelopmentEunice Kennedy Shriver National Institute Of Child Health &Human Development2009–2010
Hedgehog Signal Transduction Across The Cell MembraneNational Institute Of General Medical Sciences2006–2010
Breast Cancer Treatment With Antibody Targeted T CellsNational Cancer Institute2002–2006
Cornell-Rockefeller-Sloan-Kettering MST ProgramNational Institute Of General Medical Sciences1994–1996
Rockefeller-Cornell-Sloan Kettering MST ProgramNational Institute Of General Medical Sciences1993
B Cell Function And Antigen-Specific Immune ResponseNational Cancer Institute1987
Reconstitution Of Immunologic Reactivity In Marrow Graft RecipientsNational Cancer Institute1985–1986